uniQure Announces Update on U.S. Phase I/II Clinical Trial
~ AMT-130 continues to be generally well-tolerated across both dose cohorts ~ ~ Patients treated with AMT-130 show preserved function compared to baseline...
Source: globenewswire.com
Page 6 - Interim Analysis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Interim Analysis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Interim Analysis Today - Breaking & Trending Today
John Harsh, PhD: Interim Results Show Once-Nightly ON-SXB Dose is Preferred by Patients
Patients participating in the open-label extension trial had a few months for titration, more than 24 months for stable dosing, and a one-week follow up.
Source: hcplive.com
Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023
– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient... | June 10, 2023
Source: marketscreener.com
AbbVie Releases New Data Demonstrating Breadth of Its Gastroenterology Portfolio at 2023 Digestive Disease Week®
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced it will present 29 abstracts during the 2023 Digestive Disease Week (DDW) Annual Meeting, May 6-9, 2023,...
Source: prnewswire.com
AAN 2023: Ocrevus for MS found to help Black, Hispanic patients | No new relapses or worse disability seen for 90% for 1 year in trial
More than 90% of Black and Hispanic MS patients experienced no new relapses or disability worsening after one year of Ocrevus treatment.
Source: multiplesclerosisnewstoday.com